Cyclooxygenase 2 Promotes Parathyroid Hyperplasia in ESRD

Overview

Journal J Am Soc Nephrol

Specialty Nephrology

Date 2011 Feb 22

PMID 21335517

Citations 6

Authors

Qian Zhang

Junsi Qiu

Haiming Li

Yanwen Lu

Xiaoyun Wang

Junwei Yang

Shaoqing Wang

Liyin Zhang

Yong Gu

Chuan-Ming Hao

Jing Chen

Affiliations

Soon will be listed here.

Abstract

Hyperplasia of the PTG underlies the secondary hyperparathyroidism (SHPT) observed in CKD, but the mechanism underlying this hyperplasia is incompletely understood. Because aberrant cyclooxygenase 2 (COX2) expression promotes epithelial cell proliferation, we examined the effects of COX2 on the parathyroid gland in uremia. In patients with ESRD who underwent parathyroidectomy, clusters of cells within the parathyroid glands had increased COX2 expression. Some COX2-positive cells exhibited two nuclei, consistent with proliferation. Furthermore, nearly 78% of COX2-positive cells expressed proliferating cell nuclear antigen (PCNA). In the 5/6-nephrectomy rat model, rats fed a high-phosphate diet had significantly higher serum PTH levels and larger parathyroid glands than sham-operated rats. Compared with controls, the parathyroid glands of uremic rats exhibited more PCNA-positive cells and greater COX2 expression in the chief cells. Treatment with COX2 inhibitor celecoxib significantly reduced PCNA expression, attenuated serum PTH levels, and reduced the size of the glands. In conclusion, COX2 promotes the pathogenesis of hyperparathyroidism in ESRD, suggesting that inhibiting the COX2 pathway could be a potential therapeutic target.

Citing Articles

Identification of key biomarkers based on the proliferation of secondary hyperparathyroidism by bioinformatics analysis and machine learning.

Shen A, Shi J, Wang Y, Zhang Q, Chen J PeerJ. 2023; 11:e15633.

PMID: 37456892 PMC: 10340109. DOI: 10.7717/peerj.15633.

Mechanism of calcitriol regulating parathyroid cells in secondary hyperparathyroidism.

Xiang Z, Wang M, Miao C, Jin D, Wang H Front Pharmacol. 2022; 13:1020858.

PMID: 36267284 PMC: 9577402. DOI: 10.3389/fphar.2022.1020858.

Molecular Mechanisms of Parathyroid Disorders in Chronic Kidney Disease.

Hassan A, Khalaily N, Kilav-Levin R, Nechama M, Volovelsky O, Silver J Metabolites. 2022; 12(2).

PMID: 35208186 PMC: 8878033. DOI: 10.3390/metabo12020111.

Parathyroid Cell Proliferation in Secondary Hyperparathyroidism of Chronic Kidney Disease.

Naveh-Many T, Volovelsky O Int J Mol Sci. 2020; 21(12).

PMID: 32570711 PMC: 7352987. DOI: 10.3390/ijms21124332.

Oxylipin profiling of human plasma reflects the renal dysfunction in uremic patients.

Hu D, Luo Y, Li C, Zhou C, Li X, Peng A Metabolomics. 2019; 14(8):104.

PMID: 30830362 DOI: 10.1007/s11306-018-1402-4.

References

Sanchez P, Salgado L, Ferreri N, Escalante B . Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension. 1999; 34(4 Pt 2):848-53. DOI: 10.1161/01.hyp.34.4.848. View

Harris R . Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology. 2009; 17(2):55-67. DOI: 10.1007/s10787-009-8049-8. View

Arnold A, Brown M, Urena P, Gaz R, Sarfati E, Drueke T . Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest. 1995; 95(5):2047-53. PMC: 295791. DOI: 10.1172/JCI117890. View

Canalejo A, Canadillas S, Ballesteros E, Rodriguez M, Almaden Y . Importance of arachidonic acid as a mediator of parathyroid gland response. Kidney Int Suppl. 2003; (85):S10-3. DOI: 10.1046/j.1523-1755.63.s85.4.x. View

Smith W, Garavito R, Dewitt D . Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996; 271(52):33157-60. DOI: 10.1074/jbc.271.52.33157. View

Denda M, Finch J, Slatopolsky E . Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis. 1996; 28(4):596-602. DOI: 10.1016/s0272-6386(96)90473-4. View

Parfitt A . The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int. 1997; 52(1):3-9. DOI: 10.1038/ki.1997.297. View

Canadillas S, Canalejo R, Rodriguez-Ortiz M, Martinez-Moreno J, Estepa J, Zafra R . Upregulation of parathyroid VDR expression by extracellular calcium is mediated by ERK1/2-MAPK signaling pathway. Am J Physiol Renal Physiol. 2010; 298(5):F1197-204. DOI: 10.1152/ajprenal.00529.2009. View

Goodman W, Quarles L . Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2007; 74(3):276-88. DOI: 10.1038/sj.ki.5002287. View

10.

Hao C, Breyer M . Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol. 2007; 70:357-77. DOI: 10.1146/annurev.physiol.70.113006.100614. View

11.

Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E . Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron. 1994; 68(2):221-8. DOI: 10.1159/000188261. View

12.

Yamaguchi S, Yachiku S, Morikawa M . Analysis of proliferative activity of the parathyroid glands using proliferating cell nuclear antigen in patients with hyperparathyroidism. J Clin Endocrinol Metab. 1997; 82(8):2681-8. DOI: 10.1210/jcem.82.8.4117. View

13.

Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K . Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol. 2004; 15(10):2579-87. DOI: 10.1097/01.ASN.0000141016.20133.33. View

14.

Shvil Y, Naveh-Many T, Barach P, Silver J . Regulation of parathyroid cell gene expression in experimental uremia. J Am Soc Nephrol. 1990; 1(1):99-104. View

15.

Chang C, Ma B, Pang X, Wu T, Hung C . Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther. 2009; 17(8):1365-72. PMC: 2835247. DOI: 10.1038/mt.2009.118. View

16.

Kifor O, Moore Jr F, Wang P, Goldstein M, Vassilev P, KIFOR I . Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab. 1996; 81(4):1598-606. DOI: 10.1210/jcem.81.4.8636374. View

17.

Tominaga Y, Tsuzuki T, Uchida K, Haba T, Otsuka S, Ichimori T . Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int. 1999; 55(4):1375-83. DOI: 10.1046/j.1523-1755.1999.00396.x. View

18.

Gardner D, Brown E, Attie M, Aurbach G . Prostaglandin-mediated stimulation of adenosine 3',5'-monophosphate accumulation and parathyroid hormone release in dispersed human parathyroid cells. J Clin Endocrinol Metab. 1980; 51(1):20-5. DOI: 10.1210/jcem-51-1-20. View

19.

Dusso A, Sato T, Arcidiacono M, Alvarez-Hernandez D, Yang J, Gonzalez-Suarez I . Pathogenic mechanisms for parathyroid hyperplasia. Kidney Int Suppl. 2006; (102):S8-11. DOI: 10.1038/sj.ki.5001595. View

20.

Ohta K, Manabe T, Katagiri M, Harada T . Expression of proliferating cell nuclear antigens in parathyroid glands of renal hyperparathyroidism. World J Surg. 1994; 18(4):625-8; discussion 628-9. DOI: 10.1007/BF00353781. View